glp-1 drug tirzepatide Use of the dual GIP/GLP-1 (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with drugs among patients with type 2 diabetes, a large retrospective cohort Semaglutide & Tirzepatide Weight Loss

An analysis published this week in JAMA Internal Medicine found that most participants in a clinical trial who were assigned to stop taking tirzepatide (Zepbound from Eli Lilly) not only regained significant amounts of the weight they had lost on the drug, but they also saw their cardiovascular and metabolic improvements slip away

They can reduce albuminuria (protein in the urine), which is a marker of kidney damage [8, 10]

Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)

Additionally, it is one of three drugs approved to treat obesity in adolescents 12 years and older, with Qsymia and Wegovy being the other two

For context, metformin (the traditional first-line medication) typically produces 0.5-1.0 percentage point reductions